Gastrointestinal Neoplasms Clinical Trial
Official title:
Dose Finding Study of S-1, Oxaliplatin, and Irinotecan Combination Chemotherapy for Patients With Inoperable Advanced or Metastatic Gastrointestinal Cancers
This study will attempt to determine the feasibility of combination of Oxaliplatin, Irinotecan, and S-1, the maximum tolerated dose and the recommended doses of the agents used, and to preliminarily evaluate the antitumor activity in untreated patients with advanced gastrointestinal cancer.
Oxaliplatin or irinotecan has shown a considerable anti-tumor activity, when used in
combination with 5-fluorouracil (5-FU) in patients with gastrointestinal (GI) cancer.
Oxaliplatin, irinotecan, and 5-FU have different mechanisms of actions and do not share the
toxicity profiles. Since they have a synergistic effect, many clinical trials have been
conducted recently to evaluate the efficacy of triplet combination consisting of
oxaliplatin, irinotecan, and 5-FU, and demonstrated that the triple combination regimen was
effective and resulted in survival benefits with favorable toxicity profiles.
S-1 and capecitabine are novel oral fluoropyrimidines and different phase III trials have
shown that these oral agents are at least as active and effective as 5-FU with a superior
safety profile.
Biweekly triple combination of S-1 with oxaliplatin and irinotecan (OIS) is an interesting
alternative to increase convenience and to simply the treatment delivery.
In the present study, we attempt to determine the feasibility of OIS combination, the
maximum tolerated dose and the recommended doses of the agents used, and to preliminarily
evaluate the antitumor activity in untreated patients with advanced gastrointestinal cancer.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Completed |
NCT05178095 -
Artificial Intelligence in Colonic Polyp Detection
|
N/A | |
| Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
| Not yet recruiting |
NCT05552729 -
Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02871245 -
Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery
|
N/A | |
| Not yet recruiting |
NCT02860429 -
Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma
|
Phase 4 | |
| Completed |
NCT04694521 -
Outcomes of Side-to-end Versus End-to-end Colorectal Anastomosis in Non-emergent Sigmoid and Rectal Cancers: Randomized Controlled Clinical Trial
|
N/A | |
| Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
| Recruiting |
NCT02196935 -
Los Angeles Prospective GI Biliary and EUS Series
|
||
| Completed |
NCT00190801 -
Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma
|
Phase 2 | |
| Completed |
NCT00289445 -
Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
|
Phase 1/Phase 2 | |
| Completed |
NCT04010227 -
Telephone Support for Advanced Gastrointestinal Cancer Patients and Caregivers
|
N/A | |
| Recruiting |
NCT03330964 -
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
|
N/A | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Recruiting |
NCT05322486 -
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
|
||
| Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
| Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT02672774 -
Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers
|
N/A | |
| Completed |
NCT02444572 -
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
|
Phase 4 |